MannKind licenses Afrezza to Sanofi
MannKind Corp. (NASDAQ:MNKD) granted Sanofi (Euronext:SAN; NYSE:SNY) exclusive, worldwide rights to develop and commercialize Afrezza inhaled insulin to treat adults with Type I and II diabetes. MannKind will receive $150 million in cash up front and is eligible for up to $775 million in milestones. The milestones include $75 million in near-term manufacturing...
Read the full 260 word article
User Sign in
Trial Subscription
Get a 4-week free trial subscription to BioCentury Extra
Article Purchase
$50 USD
